This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sirolimus Based Immunosuppression for Patients Undergoing Kidney Transplantation in the Eurotransplant Senior Program (ESP)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2007 by Medical University of Vienna.
Recruitment status was:  Active, not recruiting
Information provided by:
Medical University of Vienna Identifier:
First received: April 17, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted

The Eurotransplant Senior Program (ESP) started in 1999 with local allocation of kidneys from deceased donors elder than 65 years to recipients elder than 65 years. The requirements for immunosuppression in this group of patients are high due to the large amount of comorbidities.

This prospective randomized trial compared the standard immunosuppressive protocol based on cyclosporine A (CyA) used at our center within the ESP, to a calcineurin inhibitor-free protocol based on sirolimus (SRL).

The aim of this study is to investigate the effect of a CNI-free therapy on the function of elderly kidneys 6 months post transplantation, measured by GFR.

Condition Phase
Kidney Function After Transplantation Outcome After Kidney Transplantation Phase 4

Study Type: Observational
Study Design: Allocation: Random Sample
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Outcome After Renal Transplantation of a Randomized Prospective Trial in the Eurotransplant Senior Program

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Estimated Enrollment: 48
Study Start Date: January 2003
Estimated Study Completion Date: December 2007

Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Recipients of the Eurotransplant Senior Program
  • negative cytotoxic crossmatch
  • signed informed consent

Exclusion Criteria:

  • High sensitized recipients (PRA > 40%)
  • Non heart Beating Donor
  • Hyperlipidemia
  • Leucocytopenia (< 3000/mm3)
  • Thrombocytopenia (< 75000/mm3)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00461357

Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Ferdinand Muehlbacher, MD Professor Medical University of Vienna; Department of Transplantation
  More Information Identifier: NCT00461357     History of Changes
Other Study ID Numbers: NTX-OFO-01
Study First Received: April 17, 2007
Last Updated: April 17, 2007

Keywords provided by Medical University of Vienna:
Old for Old
Eurotransplant Senior Program
Glomerular Filtration Rate processed this record on August 16, 2017